Company: TAK
Filing Date: 2025-10-30
Form Type: 6-K
Source: 0001395064-25-000154
Chunk: 33

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-10-30
Form: 6-K
Chunk 33
---
 ended March 31, 2025 to September 30, 2025.

<div align='center'>- 21 -</div>

Translation for reference purpose only

### IV. Financial Information
Basis of Preparation of the Condensed Interim Consolidated Financial Statements

Takeda has prepared the condensed interim consolidated financial statements in accordance with IAS 34 “Interim Financial Reporting” pursuant to Article 312 of "Ordinance on the Terminology, Forms and Preparation Methods of Consolidated Financial Statements" (Ordinance of the Ministry of Finance No. 28, 1976) (hereinafter “Ordinance on Consolidated Financial Statements”).

Takeda falls under the category listed in the upper column of item 1 of the table in Article 24-5, Paragraph 1 of the Financial Instruments and Exchange Act of Japan, and prepares Type 1 Interim Consolidated Financial Statements in accordance with the provisions of Part 1 and Part 5 of Ordinance on Consolidated Financial Statements.

<div align='center'>- 22 -</div>

Translation for reference purpose only

### 1. Condensed Interim Consolidated Financial Statements
(1) Condensed Interim Consolidated Statements of Profit or Loss

|                                                                                  |     |   | Note | Six-month Period Ended September 30, |     | JPY (millions, except per share data) |      2024 |     |     |      2025 |
|:---------------------------------------------------------------------------------|:----|--:|:-----|:-------------------------------------|:----|:--------------------------------------|----------:|:----|:----|----------:|
| Revenue                                                                          |     | 4 |      |                                      |     |                                       | 2,384,028 |     |     | 2,219,481 |
| Cost of sales                                                                    |     |   |      |                                      |     |                                       |  -781,265 |     |     |  -764,736 |
| Selling, general and administrative expenses                                     |     |   |      |                                      |     |                                       |  -538,312 |     |     |  -509,436 |
| Research and development expenses                                                |     |   |      |                                      |     |                                       |  -344,027 |     |     |  -305,373 |
| Amortization and impairment losses on intangible assets associated with products |     | 5 |      |                                      |     |                                       |  -305,245 |     |